Compass Therapeutics

BioCorRx (OTCMKTS: BICX) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$1.79
Volume: 0
5-Day Change: -3.24%
YTD Change: 83.59%
Market Cap: US$15.160M

Latest News From BioCorRx

May 16, 2023
BioCorRx Provides Business Update for the First Quarter of 2023
Revenue Increases 97% ANAHEIM, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended March 31, 2023 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented,... Read More
April 3, 2023
BioCorRx Provides Business Update for 2022
Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics ANAHEIM, CA, April 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2022 and reported on recent corporate developments.... Read More
March 7, 2023
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
BICX104 was Well Tolerated with No Serious Adverse Events Reported and Achieved 84 Days of Therapeutic Naltrexone Plasma Concentrations BICX104 Subjects Experienced Better 84-Day Treatment Adherence Than Vivitrol® Subjects Company Seeking FDA Approval for Immediate Expanded Access “Compassionate Use” of BICX104 for Over 10 Million Americans with Opioid Use Disorder BioCorRx Applying for Fast Track Designation and Also... Read More
February 23, 2023
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Dr. Andrew Mallon, CSO and Grant Principal Investigator on the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD),... Read More
January 27, 2023
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
Presentation on Thursday, February 2, 2023 at 2:00 PM ET ANAHEIM, CA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx, and Brady Granier, President and Director of... Read More
January 24, 2023
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
ANAHEIM, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Harsha Murthy was appointed to the Company’s Board of Directors. Mr. Harsha Murthy is an experienced pharmaceuticals/finance executive with expertise in pharmaceutical operations, strategy,... Read More
January 19, 2023
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update from the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx... Read More
January 11, 2023
Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
FREEHOLD, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that it has appointed Lourdes Felix to its Board of Directors. Lourdes Felix is an entrepreneur and corporate finance executive with 30 years of combined experience in capital... Read More
December 7, 2022
BioCorRx Partners with Government Plus to Expand Beat Addiction Recovery Program in United States
ANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading provider of private sector healthcare to veterans, to nationally expand its Beat Addiction Recovery Program. Ed LeTourneau, CEO of... Read More
November 15, 2022
BioCorRx Provides Business Update for the Third Quarter of 2022
ANAHEIM, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2022 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “Last month, we... Read More
October 24, 2022
BioCorRx to Present at the LD Micro Main Event XV on October 25th
BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the 15 th annual LD Micro Main Event being... Read More
October 20, 2022
BioCorRx to Participate at the LD Micro Main Event XV
BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating at the 15 th annual LD Micro Main Event... Read More
October 13, 2022
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the last subject has been enrolled in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled... Read More
September 6, 2022
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person... Read More
August 16, 2022
BioCorRx Provides Business Update for the Second Quarter of 2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “During the quarter, we dosed the first subject in the Phase I clinical trial of BICX104, an... Read More
July 13, 2022
BioCorRx to Participate in the Benzinga All Access Event on July 15th
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating in the Benzinga All Access event taking place on July 15, 2022. Mr. Granier is scheduled to present on Friday, July 15, 2022, at 10:40 A.M.... Read More
June 30, 2022
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled... Read More
June 17, 2022
BioCorRx Featured on LiveNOW from FOX
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Tom Welch, Executive Vice President of BioCorRx Inc., was featured on LiveNOW from FOX. Mr. Welch discussed BioCorRx’s pilot program with 2B3D , a virtual, augmented, and mixed reality technology company, a first-of-its-kind post-traumatic stress disorder... Read More
May 31, 2022
BioCorRx to Present at the LD Micro Invitational XII on June 7th
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the LD Micro Invitational XII which is being... Read More
May 19, 2022
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual reality technology Plans toward expanding the offering to other at-risk groups upon evaluating results of pilot with veterans BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it is... Read More
May 17, 2022
BioCorRx Business Update for the First Quarter of 2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “We are pleased to report progress on our upcoming first-in-human clinical trial of BICX104,... Read More
April 27, 2022
BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has begun the recruiting and enrollment process for its first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc.,... Read More
April 26, 2022
BioCorRx to Present at the Planet MicroCap Showcase 2022 in Las Vegas on May 4th
BioCorRx Inc. (OTCQB:BICX) (the "Company") , a developer and provider of innovative treatment programs fr substance abuse and related disorders, today announced that it will present at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022 at 3:00 PM Pacific Time/ 6:00 PM Eastern Time at the Bally's Hotel & Casino in Las Vegas, NV. Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx... Read More
April 11, 2022
BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has been awarded a supplemental grant of approximately $100,000 by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) for the first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet... Read More
April 1, 2022
BioCorRx Provides 2021 Year-End Business Update
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a year-end business update for 2021 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “In 2021, we achieved a number of important milestones and accomplishments. During the second quarter of 2021, we... Read More
March 22, 2022
BioCorRx to Participate in Two Upcoming Conferences
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will be participating in two upcoming conferences. 2022 Virtual Growth Conference Management has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. -... Read More
March 16, 2022
BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has received Independent Institutional Review Board (IRB) approval for the Company’s Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx... Read More
Assertio

COPYRIGHT ©2023 HEALTH STOCKS HUB